Results 71 to 80 of about 22,196 (255)
Alzheimer's &Dementia, Volume 21, Issue 5, May 2025.Abstract INTRODUCTION This retrospective study investigates whether exposure to levodopa/carbidopa (LA/CA) medication is associated with modified Alzheimer's disease (AD) trajectories. METHODS Multivariate analysis used cerebrospinal fluid (CSF) biomarker information included in the National Alzheimer's Coordinating Center Uniform Data Set for subjects
Zsuzsa Sárkány +3 more
wiley +1 more source
Bromocriptine for “negative” schizophrenia
Comprehensive Psychiatry, 1991 The hypothesis that the pathophysiology of negative symptoms in schizophrenia may involve relative hypoactivity of central dopaminergic neurotransmission prompts the exploration of dopamine agonist strategies in the treatment of this condition. Although the use of dopamine agonists in otherwise unmedicated schizophrenic patients often leads to the ...
Paul C. Bermanzohn +4 more
openaire +3 more sources
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2012 Background Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM).
J. Gaziano +6 more
semanticscholar +1 more source
Food Frontiers, Volume 6, Issue 3, Page 1093-1128, May 2025.Jasminum bioactives improve food preservation by providing antimicrobial and antioxidant effects, especially when incorporated into active packaging, edible films, and nanoformulations that enhance stability and controlled release. They also offer many pharmacological benefits, including anti‐inflammatory, neuroprotective, and wound‐healing properties.
Antonio Rescigno +17 more
wiley +1 more source
Movement Disorders, Volume 40, Issue 5, Page 776-794, May 2025.Abstract Objective To update evidence‐based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). Background The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorders Committee recommendations for the treatments of PD were first published in 2002 and regularly updated ...
Rob M.A. de Bie +21 more
wiley +1 more source
Oncology Report, 2012 Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated with bromocriptine-treated prolactinomas.
Chengde Wang +9 more
semanticscholar +1 more source
Advanced Science, Volume 12, Issue 14, April 10, 2025.An optimized protocol is developed to differentiate human iPSCs into pituitary organoids and the cellular composition, intercellular interactions, and spatial organization within pituitary organoids are characterized via scRNA‐seq and Stereo‐seq.
Shengjie Wang +8 more
wiley +1 more source
Research Progress of Plasma Cell Mastitis
Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.ABSTRACT Background Plasma cell mastitis (PCM), also termed mammary duct ectasia, is a chronic nonbacterial inflammatory disease characterized by mammary duct dilation and plasma cell infiltration. Due to its varied and nonspecific clinical presentation, PCM is frequently misdiagnosed as breast cancer, complicating clinical management.
Zhebin Liang, Lifeng Zhang
wiley +1 more source
Diabetes Care, 2010 OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and
J. Gaziano +6 more
semanticscholar +1 more source
Indian Journal of Pharmacology, 2012 Objective: The objective of the present study was to evaluate the effect of bromocriptine on cardiovascular complications associated with type-2 diabetes mellitus (DM).
V. Nade +3 more
semanticscholar +1 more source